Your browser is no longer supported. Please, upgrade your browser.
Eagle Pharmaceuticals, Inc.
Index- P/E143.14 EPS (ttm)0.35 Insider Own0.10% Shs Outstand13.53M Perf Week1.97%
Market Cap676.95M Forward P/E18.80 EPS next Y2.70 Insider Trans0.00% Shs Float10.13M Perf Month7.76%
Income4.90M PEG53.01 EPS next Q-0.17 Inst Own99.50% Short Float14.74% Perf Quarter9.63%
Sales186.10M P/S3.64 EPS this Y-51.50% Inst Trans0.05% Short Ratio11.77 Perf Half Y-1.17%
Book/sh12.77 P/B3.97 EPS next Y11.00% ROA1.80% Target Price50.00 Perf Year-14.91%
Cash/sh6.71 P/C7.55 EPS next 5Y2.70% ROE2.80% 52W Range33.80 - 59.99 Perf YTD8.80%
Dividend- P/FCF26.24 EPS past 5Y20.20% ROI6.50% 52W High-15.53% Beta0.65
Dividend %- Quick Ratio3.50 Sales past 5Y59.30% Gross Margin76.10% 52W Low49.91% ATR1.75
Employees108 Current Ratio3.60 Sales Q/Q21.40% Oper. Margin14.00% RSI (14)63.62 Volatility2.99% 3.65%
OptionableYes Debt/Eq0.20 EPS Q/Q392.80% Profit Margin2.70% Rel Volume0.62 Prev Close50.73
ShortableYes LT Debt/Eq0.16 EarningsNov 02 BMO Payout0.00% Avg Volume126.87K Price50.67
Recom2.20 SMA205.16% SMA505.76% SMA2007.98% Volume78,198 Change-0.12%
Nov-01-18Downgrade Cantor Fitzgerald Overweight → Neutral
Oct-31-18Downgrade Piper Jaffray Overweight → Neutral
Mar-21-18Reiterated Mizuho Underperform $37 → $40
Nov-09-17Reiterated RBC Capital Mkts Outperform $81 → $75
Sep-06-17Reiterated Mizuho Underperform $40 → $37
Jul-27-17Reiterated RBC Capital Mkts Outperform $94 → $81
Jul-27-17Reiterated Mizuho Underperform $57 → $40
May-09-17Reiterated RBC Capital Mkts Outperform $86 → $94
Jan-09-17Downgrade Mizuho Neutral → Underperform $78 → $64
Nov-16-16Downgrade Mizuho Buy → Neutral $78
Nov-03-16Upgrade Mizuho Neutral → Buy $62 → $78
Nov-03-16Reiterated RBC Capital Mkts Outperform $80 → $93
Oct-26-16Reiterated Mizuho Buy $65 → $62
Aug-16-16Reiterated Mizuho Neutral $47 → $65
Jun-20-16Downgrade Mizuho Buy → Neutral $66 → $47
May-10-16Reiterated RBC Capital Mkts Outperform $94 → $78
Mar-18-16Reiterated Mizuho Buy $81 → $71
Feb-26-16Reiterated Mizuho Buy $112 → $81
Dec-09-15Initiated Mizuho Buy $112
Jul-29-15Reiterated Piper Jaffray Overweight $94 → $119
Jan-11-21 06:50AM  
Jan-04-21 04:30PM  
Jan-03-21 02:45AM  
Dec-15-20 07:27PM  
Nov-23-20 06:50AM  
Nov-04-20 06:10AM  
Nov-02-20 12:30PM  
Oct-26-20 04:30PM  
Oct-15-20 09:20AM  
Sep-25-20 02:13PM  
Sep-24-20 11:30AM  
Sep-23-20 06:50AM  
Sep-09-20 11:07AM  
Sep-08-20 06:50AM  
Aug-19-20 06:50AM  
Aug-10-20 01:30PM  
Aug-03-20 04:30PM  
Jul-31-20 03:56PM  
Jul-17-20 11:47AM  
Jul-09-20 12:00PM  
Jun-27-20 09:28PM  
Jun-10-20 04:08PM  
May-26-20 04:30PM  
May-22-20 04:05PM  
May-14-20 11:50AM  
May-12-20 04:30PM  
May-11-20 12:30PM  
May-08-20 08:41AM  
May-07-20 06:07AM  
May-04-20 06:50AM  
Apr-29-20 04:30PM  
Apr-28-20 12:33PM  
Apr-16-20 05:24PM  
Apr-11-20 09:25AM  
Mar-30-20 06:50AM  
Mar-24-20 02:20AM  
Mar-10-20 07:55AM  
Mar-02-20 08:15AM  
Feb-24-20 12:30PM  
Feb-19-20 04:30PM  
Feb-13-20 07:50AM  
Feb-10-20 09:54AM  
Jan-13-20 06:50AM  
Jan-09-20 08:40AM  
Jan-08-20 10:18AM  
Jan-07-20 09:25AM  
Jan-06-20 06:50AM  
Dec-23-19 06:50AM  
Dec-16-19 06:50AM  
Dec-13-19 02:53PM  
Dec-11-19 11:25AM  
Dec-09-19 06:50AM  
Dec-03-19 08:45AM  
Nov-21-19 07:49AM  
Nov-20-19 06:50AM  
Nov-14-19 06:50AM  
Nov-12-19 08:15AM  
Nov-09-19 02:26PM  
Nov-05-19 10:31AM  
Oct-31-19 04:30PM  
Oct-28-19 08:02AM  
Oct-17-19 09:28AM  
Oct-07-19 06:50AM  
Oct-02-19 02:39PM  
Sep-24-19 11:30AM  
Sep-23-19 04:30PM  
Sep-10-19 07:29AM  
Sep-04-19 08:40AM  
Aug-30-19 01:49PM  
Aug-28-19 04:30PM  
Aug-20-19 04:47PM  
Aug-18-19 10:21AM  
Aug-14-19 10:29AM  
Aug-09-19 06:23AM  
Aug-08-19 08:45AM  
Eagle Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers Argatroban, an anti-coagulant thrombin inhibitor for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also includes EP-4104, a dantrolene sodium for exertional heat stroke, as well as to treat organophosphate exposure; EP-5101 (PEMFEXY) for lung cancer and mesothelioma; EGL-5385-C-1701 (fulvestrant) for breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has a strategic collaboration with Tyme Technologies, Inc. to advance oral SM-88 for the treatment of patients with cancer. Eagle Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Woodcliff Lake, New Jersey.